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Abstract
Background. There is large variability in the diagnostic approach and clinical management in 
functional movement disorders (FMD). This study aimed to examine whether opinions and clinical 
practices related to FMD have changed over the past decade. 
Methods. A survey to members of the International Parkinson and Movement Disorder Society 
(MDS).
Results. We received 864/7689 responses (denominator includes non-neurologists) from 92 
countries. Respondents were more often male (55%), younger than 45 (65%), and from academic 
practices (85%). Although the likelihood of ordering neurological investigations prior to delivering a 
diagnosis of FMD was nearly as high as in 2008 (47% versus 51%), the percentage of respondents 
communicating the diagnosis without requesting additional tests increased (27% versus 19%; 
p=0.003), with most envisioning their role as providing a diagnosis and coordinating management 
(57% versus 40%; p<0.001). Compared to patients with other disorders, 64% of respondents were 
more concerned about missing a diagnosis of another neurological disorder. Avoiding iatrogenic 
harm (58%) and educating patients about the diagnosis (53%) were again rated as the most effective 
therapeutic options. Frequent treatment barriers included lack of physician knowledge and training 
(32%), lack of treatment guidelines (39%), limited availability of referral services (48%), and cultural 
beliefs about psychological illnesses (50%). The preferred term for communication favored 
“functional” over “psychogenic” (p<0.001). 
Conclusions. Attitudes and management of FMD have changed over the past decade. Important 
gaps remain in the education of neurologists about the inclusionary approach to FMD diagnosis, and 
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Introduction
Functional movement disorders (FMD) refer to involuntary abnormal movements that are 
inconsistent and incongruent with the phenotypic range of other movement disorders.(1) In recent 
years, the terminology has shifted from “psychogenic” to “functional” movement disorders,(2) 
emphasizing the conceptual evolution from brain-mind dualism to a biopsychosocial illness model 
in luding alterations in sensorimotor and limbic brain circuits.(3-7)  FMD is estimated to represent 
from 5 to 25% of patients seen in specialized movement disorder centers.(8)  Despite the high 
frequency of this disorder in neurological settings, these patients have historically been poorly 
diagnosed and managed.  Although it is established that FMD is a ‘rule in’ diagnosis with “positive 
criteria” for phenotype-specific diagnosis,(9-11)  an exclusionary approach to diagnosis is often used, 
with unnecessary or harmful diagnostic investigations and pharmacotherapy.(12)  A decade-old 
survey of members of the International Movement Disorder Society (MDS) with experience in FMD 
treatment found substantial variability regarding opinions and clinical practices associated with 
FMD. We aimed to conduct an updated survey to determine if opinions and clinical practices have 
changed. 
Methods
The 2008 survey was reviewed and modified by members of the MDS FMD Study Group. Questions 
were added to address new education and care practices. The resulting 21-item survey 
(Supplementary material) was sent to all 7,689 MDS members via the MDS secretariat. Only 
practicing neurologists with experience in evaluating patients with FMD were asked to participate, 
which reduces the denominator to under 5,000 potential respondents (member qualifications not 
reported by MDS). The survey remained open for six weeks between August 16 and September 28, 
2018, with three reminder emails sent during this period. Participants were asked demographic 
information on age, gender, country of practice and average number of patients under their care. 
Informed consent was not required, since no personal identifying information was collected. Study 
data were collected and managed using REDCap electronic data capture tools. (13) The study 
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Statistical Analysis 
The survey data were exported from REDCap into STATA 15.1 for analyses (StataCorp LLC, College 
Station, TX 77845, USA). Clinical characteristics, demographic characteristics, and survey responses 
were summarized using descriptive statistics. Mean and standard deviation (SD) were used to 
summarize Likert scale data. All the categorical data including Likert scale data and categorized data 
from continuous variables were summarized using frequency and proportion. Frequencies and 
percentages from each response from the previous survey were compared with current survey data 
using Fisher’s exact test or Chi square test and analyzed according to gender, age, country, training 
length, patient load, type of practice, location of practice, and years of practice using Chi square 
tests. Spearman rank correlation (r) was determined among ratings within each category of 
responses (diagnosis, treatment, prognosis, and ability to manage).  
Results
There were 864 responses from MDS members in 92 countries, most from the US (21%), Europe and 
Canada (35% combined). Compared to the previous survey, a higher proportion of respondents 
practiced in countries outside North America and Europe (44% versus 25%; p<0.001).  One third of 
respondents evaluated more than 3 FMD patients per month compared to 21% in the prior survey 
(5% reported seeing over 11; previously 1%, p<0.001) (Table 1).  
A higher number of respondents reported identifying a co-morbid organic neurologic disorder 
“sometimes” or “frequently” (41% versus 20%, p<0.01); 64% were “more” or “very concerned” 
about missing another organic diagnosis in FMD patients compared to non-FMD neurological 
patients. The personal preference in 29% of respondents was for disliking “somewhat” or “very 
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In order to reach a clinically definite FMD diagnosis, the majority of respondents rely exclusively on 
neurologic examination (78%; previously 71%; p=0.007), incongruence of movements with a classical 
movement disorder (61%; previously 72%; p<0.001), and inconsistency over time (52%; previously 
57%; p=0.1) (Table 2).  Although DSM-5 no longer requires it, 12% of respondents required evidence 
of an emotional disturbance for a clinically definite diagnosis of FMD compared to 18% previously 
(p=0.005). Suggestibility, a maneuver to change the movements, was less commonly used to 
diagnose FMD (“often” or “always” in 43%; previously 47%; p<0.001). Use of a placebo to alter or 
abolish the phenotype with an inert intervention, was “never” (48%; previously 51%) or “rarely” 
(25%; previously 24%; p=0.7) used for diagnostic purposes (Table 2). Placebo use was more 
commonly reported outside the US (“sometimes”, “often”, or “always” in 32% versus 6%, p <0.001). 
Even when clinical features were incongruent and inconsistent with the diagnosis of FMD, 47% of 
respondents requested standard neurological investigations to rule out other neurologic diseases 
before diagnosing the patient with FMD, compared to 51% in 2008, a non-significant difference 
(Figure 1). On the other hand, the percentage of respondents informing patients about a clinically 
definite diagnosis of FMD during their initial assessment, without requesting additional 
investigations, increased from 19% to 27% (p=0.003). Respondents in the US employed this 
approach over twice as often as those outside the US (56% versus 19%; p<0.001). The likelihood of 
ordering neurological investigations prior to delivering a diagnosis of FMD was also dependent on 
the number of FMD patients seen per month: 38% of practitioners seeing 7 FMD patients per 
month did not routinely order additional diagnostic studies compared to 19% of those seeing  1 
FMD patients per month (p<0.001). Neither age, gender, or number of years in practice affected the 
respondents’ approach. 
Electrophysiology was used by 60% (versus 66% in 2008) on a regular basis for a laboratory-
supported diagnosis of functional myoclonus or tremor; 33% (previously 24%) had no access to such 










This article is protected by copyright. All rights reserved
Electrophysiologic testing was more commonly used outside the US (for confirmation in “all” or 
“selected” cases in 45% versus 27%; p<0.001); survey respondents outside the US were also more 
likely to discuss test results with patients to explain the diagnosis of FMD (p <0.001). 
The majority of respondents considered their main responsibility to provide a diagnosis and 
coordinate interdisciplinary management (57% versus 40% in 2008; p<0.001). Only 1% restricted 
their role to providing the diagnosis (previously, 3%). Practitioners in small centers were less likely to 
coordinate long-term management compared to those from large city locations (36% versus 62%; 
p=0.005).
Predictors of the Diagnosis
A non-FMD diagnosis was“somewhat” or “very/extremely” influenced by a prior “organic” diagnosis 
by an experienced neurologist (43%/30%); absence of associated non-physiologic deficits on 
neurologic examination (34%/33%), lack of psychiatric history (33/22%), evidence of physical injury 
(37/26%), and extremes of age (<6 or >75 years) (36/31%). Male gender (69%), normal social 
function (45%), normal work load with little or no employment disruption (42%) were rated as “not 
influential” or “mostly not influential”. 
Approach to Management
Respondents “always” or “most of the time” discussed positive signs on physical examination (49%), 
the potential for reversibility or improvement (90%), the potential role of psychological factors 
(85%), the diagnostic label (78%), and the changes in brain function (70%). Printed or online 
educational materials were “always” or “most of the time” provided by 82%. Survey respondents 
with most FMD patients per month were most likely to “always” or “most of the time” demonstrate 
positive physical signs on examination to patients compared with respondents with fewest FMD 
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In terms of treatment practices in 2008, two thirds of practitioners referred patients to psychiatrists 
or mental health specialists while also providing personal follow-up. Recognizing the importance of 
access to treatment providers on referral practices, we asked in the current survey to which services 
clinicians could readily refer patients for treatment in their region. Access was available to general 
psychiatry in 56%, neuropsychiatrist or a psychiatrist with FMD experience in 38%, general 
psychologist or psychotherapist in 40%, psychologist or psychotherapist experienced in FMD in 22%, 
rehabilitation or physiotherapy specialist in 49%, psychiatric inpatient services in 19%, inpatient 
multidisciplinary rehabilitation in 18% and other specialty clinics in 5%. Referrals to psychologists, 
rehabilitation specialists or physiotherapists was more readily available in the US compared to other 
countries (p<0.001).
In cases with a dominant clinically definite diagnosis of FMD where a comorbid organic disorder was 
suspected, the majority of respondents (80%) chose to determine the major source of disability and 
prioritize treatment of that symptom, regardless of whether it was considered organic or functional 
(no previous data available for comparison).
Perceived Effectiveness of Treatment Strategies
Management modalities believed to be “very” or “extremely” effective by over one third of 
respondents were avoiding iatrogenic harm (58%), patient education (53%), referral to rehabilitation 
services (40%), and psychotherapy with antidepressive/anxiolytic treatment (35%). Most treatment 
strategies were rated higher in perceived effectiveness compared to 2008 (Figure 2A). 
Limitations in Ability to Manage FMD Patients
Factors considered as “often” or “always” limiting the management of patients with FMD by over 
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missing availability of referral services (48%; previously 33%), lack of treatment guidelines (39%; not 
previously asked) and lack of physician knowledge and training (32%, not previously asked) 
(Supplementary Table S1). The role of ongoing litigation was less frequently cited as limiting FMD 
management (25%; previously 37%). Lack of physician knowledge and training and lack of treatment 
guidelines were more often cited as treatment barriers by respondents in non-US countries (37% 
versus 16% and 42 versus 25%, respectively; p<0.001). 
Predictors of Prognosis
Compared to 2008, greater weight in predicting a favorable prognosis was given to the type of 
movement (tremor or chorea vs. dystonia or ataxia), pharmacologic treatment of specific movement 
impairment, less extensive disability, and younger age when developing the movement disorder 
(Figure 2B). Similar to the prior survey, the most important factor in predicting a favorable prognosis 
was considered the acceptance of the diagnosis by the patient, rated as “extremely important” in 
61% (previously 60%).
Terminology
Compared to 2008, the preferred terms for communication with other healthcare professionals 
shifted mostly to “functional” (63% in 2018 vs 46% in 2008) from “psychogenic” (35% in 2018 vs 59% 
in 2008) (p<0.001, Figure 3A). “Functional movement disorder” was also the preferred term for 
communication with the lay public (87% in 2018 versus 37% in 2008) (Figure 3B). 
Discussion
Expert opinions and clinical practices in managing FMD continue to vary widely among neurologists 
with movement disorder expertise. Despite efforts over the past decade to establish “positive” 
diagnostic criteria,(9, 11) FMD remains an exclusionary diagnosis for nearly half of the MDS 
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towards making an inclusionary clinical diagnosis of FMD, educating patients by demonstrating 
“positive signs”, and providing consistent educational resources were features among practitioners 
with the highest number of  FMD patients per month, plausibly reflecting an increased comfort level 
with the certainty of the diagnosis. The significantly higher number of respondents evaluating more 
than three patients with FMD per month (34% vs. 21%) is likely reflective of better recognition of 
FMD rather than a true increase in prevalence. Differences in approaches to diagnosis and 
management of FMD were only partially explained by different practice patterns between countries, 
and were not due to differences in age, gender, or years in practice by survey respondents.  
Challenges in Reaching a Diagnosis 
Over one quarter of survey respondents were comfortable in communicating a diagnosis of FMD 
without requesting additional neurologic tests, a significantly higher percentage compared to a 
decade ago. Although 75% rely on positive signs on neurological examination to make a diagnosis of 
FMD, 64% were more concerned about misdiagnosis in FMD compared to other neurologic 
conditions, indicating a need for additional education in neurology training and continued medical 
education.(14, 15)  Interestingly, incongruence of movements with a recognized movement disorder 
was less endorsed as a reliable way to reach a diagnosis of FMD (59% vs. 71%). This may reflect an 
increasing awareness that diagnosis by incongruity with other neurological conditions is, in many 
ways, also a diagnosis of exclusion and perhaps  increasing recognition of unusual and hard to 
classify movement disorder phenotypes with genetic or autoimmune background.(16, 17) 
Adding to diagnostic uncertainty, the percentage of respondents identifying co-morbid “functional” 
and “organic” neurologic disorders “sometimes” or “frequently” doubled compared to the last 
survey (41% versus 20%). Although comorbid FMD and neurodegenerative disorders have recently 
been described and may be underappreciated in the literature,(18, 19) our survey cannot determine 
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As the co-occurrence of FMD with an “organic” disease diagnosis is not rare, additional baseline 
diagnostic investigation may be justified even in people with clinically definite FMD. 
The new survey appropriately reflected the recognition that psychological stress factors are not a 
required feature for a clinically definite diagnosis of FMD. Nevertheless, 12% of survey respondents 
were unaware of the fact that an emotional disturbance is no longer a required diagnostic feature 
for functional neurologic disorder per DSM-5(20). We found a high percentage of practitioners 
performing electrophysiologic testing on a regular basis for diagnostic confirmation of functional 
tremor and myoclonus, with considerable differences between countries in practice patterns and 
access to testing. Survey respondents outside of the US were significantly more likely to use 
electrophysiology to support an FMD diagnosis, and were about twice as likely to have access to 
such testing. The lack of movement disorder specialists trained in electrophysiologic testing in the 
US and elsewhere remains a barrier towards “laboratory-supported” diagnostic criteria for 
functional tremor and myoclonus.(10, 11)  For other phenotypes, the absence of a laboratory “gold 
standard” to distinguish FMD from “organic” disorders remains a challenge.(21)  The use of placebo 
for diagnostic purposes was more commonly reported in countries outside the US which may reflect 
differences in cultural and litigation practices.  
It is important to note that several studies have shown the rate of misdiagnosis in FMD to be low 
and not unlike that of other neurologic disorders.(22, 23)  In fact, there is reason to believe that 
functional neurologic disorders are often undiagnosed and may be “hiding in plain sight.”(24) By 
contrast, almost two thirds of our survey respondents indicated to be “very concerned” or “more 
concerned” about missing a separate organic diagnosis in patients with FMD compared to patients 
with other diagnoses.
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As is the case with diagnosis, the approach to management and prognostic factors continued to 
show considerable variability. The avoidance of iatrogenic harm and education of patients about 
their diagnosis were again rated as most important. Studies have not shown consistent benefit in 
outcomes from patient education alone compared to standard medical care, although patient 
education is arguably a desirable endpoint of its own.(25) Although over 50% of survey respondents 
acknowledged their role in providing ongoing care for patients with FMD beyond establishing the 
diagnosis, practitioners at small centers were only half as likely to assume this role, possibly due to 
general access problems in their practice or being less comfortable in managing FMD. It is also of 
concern that almost one third of respondents prefer not seeing patients with FMD in their practice, 
likely reflecting ongoing stigma towards this diagnosis, misinformation (e.g., confusion with 
malingering), and system-based issues such as lack of available treatment services. 
 
Lack of access to both mental healthcare providers and rehabilitation specialists remain important 
limitations for treatment. Compared to 2008, survey respondents indicated greater confidence for 
positive treatment outcomes but the lack of available treatment services perceived as a greater 
barrier (48% versus 33%). This may reflect an increased awareness of the efficacy of these 
treatments and therefore a greater urgency to make a referral than before. Of note, our survey only 
asked for “ready access to treatment providers” and is therefore not directly reflective of actual 
treatment practices. “Cultural beliefs about psychological illnesses” was highlighted as a treatment 
barrier by half of survey respondents, indicating an opportunity for improved education and 
advocacy. Finally, lack of treatment guidelines and lack of physician knowledge and training were 
seen as important barriers especially in countries outside the US. The acceptance by patients of the 
diagnosis was again seen as the most important predictive factor of a favorable prognosis highlights 
the importance of engaging patients in their diagnosis and treatment. Towards this aim, a number of 
publications in recent years have outlined successful communication strategies in explaining a 
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Finally, we documented a clear change in the preference in terminology from “psychogenic” and 
“stress-related” towards “functional movement disorders” when communicating with both 
healthcare providers and the lay public. This change in terminology is reflected in the recent FMD 
literature,(2, 15) although we acknowledge a potential bias in the survey due to changing the 
wording in the stems of questions from “psychogenic” in 2008 to “functional”.
Limitations
This survey-based research may have biases introduced by a greater participation of clinicians from 
academic centers with interest in FMD. We could not calculate the percentage of movement 
disorders neurologists, primarily responsible for the care of these patients, because the MDS 
membership database lacks this information. We assume that the participation of non-clinicians is 
likely negligible. The current survey gained more responses from countries outside of the US 
compared to the past survey in 2008, which is a limiting factor in direct comparisons of treatment 
practices.
Conclusions 
Opinions and practices in clinical management of FMD are changing. The majority of clinicians now 
acknowledge their role in coordinating care for patients and express greater optimism in benefits 
from treatment compared to a decade ago. Remaining gaps towards best practices exist in educating 
neurologists on reaching a diagnosis of FMD based on positive diagnostic signs rather than on an 
exclusionary approach. Importantly, limited access to treatment resources for FMD continues to 
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Legends
Figures
Figure 1. Approach to delivering the diagnosis in clinically definite FMD in 2008 versus 2018. 
Columns marked with an asterisk indicate a p-value <0.05.  
Figure 2A. Perceived effectiveness of specific treatment strategies; Figure 2B. Importance of various 
factors in predicting a better prognosis of FMD, survey results from 2008 versus 2018. Rows marked 
with an asterisk indicate a p-value <0.05.  
Figure 3A. Preferred terms when communicating with medical professionals, when respondents 
were asked to rate ‘top three’.
Figure 3B. Preferred terms when communicating with lay public, when respondents were asked to 
rate ‘top three’.
Tables
Table 1. Demographics of Survey Respondents and Practice Characteristics 
An asterisk (*) denotes an overall significant difference (p<0.05) between survey responses in 2008 
and 2018.  
Table 2.  Approaches in Reaching the Diagnosis of FMD
An asterisk (*) denotes an overall significant difference (p<0.05) between survey responses in 2008 
and 2018.  
Supplementary Table S1. Limitations of Ability to Manage FMD
An asterisk (*) denotes an overall significant difference (p<0.05) between survey responses in 2008 
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Table 1 








N % N % 
Gender     <0.001* 
   Male 313 68 346 54.7  
   Female 150 32 286 45.3  
Age (years)     <0.001* 
   25-35 72 16 189 29.8 <0.001 
   36-45 172 37 220 34.7 0.408 
   46-55 144 31 115 18.1 <0.001 
   56-65 59 13 85 13.4 0.786 
   >66 16 4 25  3.9 0.749 
Country     <0.001* 
   US 199 43 135 21.3 <0.001 
   Europe + Canada 149 32 222 35.0 0.302 
   Others 118 25 277 43.7 <0.001 
Years in practice (Post-Residency)     <0.001* 
   < 5 years 110 24 241 38.0 <0.001 
   6-10 years 88 19 116 18.3 0.814 
   11-15 years 85 18 81 12.8 0.013 
   16-20 years 67 14 64 10.1 0.030 
   >21 years 114 25 132 20.8 0.144 
Length of fellowship training     0.036* 
   None 92 20 107 16.9 0.204 
   1 year 100 22 124 19.6 0.404 
   2 years 126 28 154 24.3 0.261 
   3 years 52 11 76 12.0 0.775 
   4 years 89 19 173 27.3 0.003 
Type of practice     0.726 
   Academic clinician 133 29 191 30.1  
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   Community practice 77 17 95 15.0  
Practice setting     0.132 
   Small center 14 3 33  5.2  
   City population > 50,000 161 35 236 37.2  
   City population >1 million 285 62 365 57.6  
Number of FMD patients seen per 
month 
        <0.001* 
   < 1 148 32.0 141 22.3 <0.001 
   1-3 220 47.5 277 43.8 0.220 
   4-6 63 13.6 127 20.1 0.006 
   7-10 26 5.6 54 8.5 0.078 
   >11 6 1.3 34 5.4 <0.001 
Number of movement disorder 
patients seen per month 
        <0.001* 
   < 30 63 13.7 167 26.3 <0.001 
   31-45 100 21.7 139 21.9 1.00 
   46-60 82 17.8 100 15.8 0.367 
   61-80 82 17.8 57 9.0 <0.001 
   >80 133 28.9 171 27.0 0.495 
Presence of co-morbid organic 
neurologic disorder  
        <0.001* 
   Never 56 12.2 43 6.8 0.003 
   Very rarely 198 43.0 151 23.8 <0.001 
   Rarely 115 25.0 182 28.7 0.169 
   Sometimes 70 15.2 225 35.5 <0.001 
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Table 2 
   2008  2018  p-value  
Role in assessing FMD   <0.001* 
To provide only a diagnosis 15(3%) 6 (0.9%)   
secure expert management 262(52%) 239 (37.7%)   
coordinate interdisciplinary long-term management 202(40%) 358 (56.5%)   
diagnosis and manage personally  25(5%) 31 (4.9%)   
Role of Electrophysiology     0.002* 
do not have access 121(24%) 210 (33.1%)   
do not think electrophysiology is useful 45(9%) 43 (6.8%)   
Discussion of Electrophysiology results      <0.001* 
Never/rarely  202(40%) 193 (30.5%)   
Sometimes 196(39%) 176(27.8%)   
Often/always 106(21%) 265(21.2%)   
Necessary for clinical definite diagnosis of FMD       
emotional disturbance 88(17.5%) 73 (11.5%)  0.005* 
psychiatric  disturbance 38(7.5%) 75 (11.8%)  0.017* 
multiple somatizations 111(22%) 119 (18.8%)  0.182 
functional signs  on neurological exam 358(71%) 495 (78.1%)  0.007* 
Incongruent exam  361(71.6%) 385 (60.7%)  <0.001* 
inconsistent exam over time 285(56.5%) 327 (51.6%)  0.106 
Use of Suggestions       <0.001* 
Never/rarely  128 (19%) 150 (23.7%)   
Sometimes 158(34%) 211 (33.3%)   
Often 139(30%) 194 (30.6%)   
Always 79(17%) 79 (12.5%)   
Use of Placebo    0.720 
Never/rarely 378 (75%) 468 (73.8%)  
Sometimes N/A 110 (17.4%)  
Often N/A 49 (7.7%)  
Always N/A 7 (1.1%)  
 
A
cc
ep
te
d
 A
rt
ic
le
A
cc
ep
te
d
 A
rt
ic
le
A
cc
ep
te
d
 A
rt
ic
le
